Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 344477
License Grant
Licensor hereby grants to Licensee (a) an exclusive (even as to Licensor and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)), license under the Licensor Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)) license under the Licensor Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Licensee Product(s) in the Licensed Field in the Territory during the Term.
License Property
Licensor Patents means all Patent Rights Controlled by Licensor or its Affiliates (Sale Transactions or Licensor Acquisition) that Cover the Licensor Platform Technology, including the Patent Rights listed (Licensor IP).
U.S. patent 5,906,936 – Endowing lymphocytes with antibody specificity
U.S. patent 7,741,465 – Chimeric receptor genes and cells transformed therewith
U.S. patent 6,319,494 – Chimeric chains for receptor-associated signal transduction pathways
Licensee Product means (a) as it relates to an Licensee Target, other than an Additional Target, a CAR Product directed against such particular Licensee Target based upon or generated using the constructs or complexes for CAR Products generated in the conduct of the Preclinical Development Plan for such Licensee Target; and (b) as it relates to an Licensee Additional Target (if any), either a CAR Product or a TCR Product (but not both) directed against such Additional Target based upon or generated using the constructs or complexes for CAR Products or TCR Products. as the case may be, generated in the conduct of the Preclinical Development Plan for such Additional Target.
CAR Product means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.
Licensee Target means a Target specified as an Licensee Target (Target Selection) or any New Target or Additional Target selected by Licensee. For clarity, Licensee Target shall exclude any Removed Target.
Target means an antigen expressed on or in a tumor cell.
Field of Use
Field of use is for the development activities of certain cell-based therapy products. Licensed Field means any and all uses.
IPSCIO Record ID: 336300
License Grant
Licensor hereby grants to Licensee (a) an exclusive (even as to Licensor and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)), license under the Licensor Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Agreement (Sublicenses)) license under the Licensor Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Licensee Product(s) in the Licensed Field in the Territory during the Term.
License Property
Licensor Patents means the Patent Rights to the antibody nucleic acid sequences provided to Licensee under this Agreement, along with the polypeptide sequences encoded by said nucleic acid sequences, Derivatives of said polypeptide sequences, and nucleic acids encoding said Derivatives.
Licensee Product means (a) as it relates to a Licensee Target, other than an Additional Target, a CAR Product directed against such particular Licensee Target based upon or generated using the constructs or complexes for CAR Products generated in the conduct of the Preclinical Development Plan for such Licensee Target; and (b) as it relates to a Licensee Additional Target (if any) either a CAR Product or a TCR Product (but not both) directed against such Additional Target, based upon or generated using the constructs or complexes for CAR Products or TCR Products, as the case may be. generated in the conduct of the Preclinical Development Plan for such Additional Target. For clarity, upon Licensor’s exercise of its option to obtain exclusive rights to an Licensor Optioned Target, Licensee Products shall exclude Licensor Optioned Products.
CAR Product means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.
Licensee Target means a Target specified as a Licensee Target pursuant to this agreement (Target Selection) or any New Target selected by Licensee. For clarity, Licensee Target shall exclude any Removed Target. Licensee Target excludes any Licensor Optioned Target.
Target means an antigen expressed on or in a tumor cell.
Field of Use
Field of use is for the development activities of certain cell-based therapy products. Licensed Field means any and all uses.
The Parties will jointly create preclinical development plans through IND filing with the FDA for the research and development of CAR-based product candidates that target certain antigens expressed on the cell surface of various cancers.
IPSCIO Record ID: 256218
License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers, under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.
Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al
Eshhar-NIH patent US 8,211,422, Eshhar et al
Eshhar-NIH pending application [US 13/281,560, Eshhar et al
KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.
Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.
IPSCIO Record ID: 363524
License Grant
The parties are collaborating to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Licensor’s proprietary platform. Licensee and Licensor agreed to engage in up to three different research programs, each covering a collaboration target. Licensee has sole responsibility for all development and commercialization activities (including regulatory filing and approval).
License Property
CAR-NK cells are known to be effective against hematological malignancies, and a growing number of preclinical findings indicate that they have activity against non-hematological neoplasms.
Field of Use
The collaboration and license agreement is to develop novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens.
Licensee is developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
